Allstate Investment Management’s Vertex Pharmaceuticals VRTX Stock Holding History

Allstate Investment Management’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	$3.65M	Buy	+12,636	New	+$3.85M	0.11%	128

Other funds holding VRTX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

Allstate Investment Management's VRTX Position: Q4 2022 in Review

Allstate Investment Management opened a new position in Vertex Pharmaceuticals (VRTX) in Q4 2022: 12,636 shares worth $3.65M. The stake represents 0.11% of the portfolio and ranks #128 among its holdings.

1,223 funds tracked by Wall St. Rank hold VRTX as of Q4 2022.

Allstate Investment Management held 12,636 shares of Vertex Pharmaceuticals worth $3.65M as of Q4 2022.
Vertex Pharmaceuticals was a new Allstate Investment Management position in Q4 2022.
Vertex Pharmaceuticals made up 0.11% of Allstate Investment Management's portfolio in Q4 2022, its #128 holding.
1,223 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q4 2022.

Based on Allstate Investment Management's 13F filing for Q4 2022, filed 14 Feb 2023.